Maze Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
None.
Rule 10b5-1 Trading Plans
During the three months end December 31, 2025, the following directors and/or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” in each case as defined in Item 408 of Regulation S-K:
| Character of Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Action · Date of · Rule · Non-Rule · Nature of · AggregateNumber · Duration of Trading | ||||||
| Name and Title · Taken · Action · 10b5-1* · 10b5-1** · Trading · of Securities · Arrangement(1) | ||||||
| Jason Coloma, Chief Executive Officer | Adopted(1) | October 13, 2025 | X | Sale | 103,504 | 2/11/2026-7/14/2026 |
| *Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | ||||||
| **"Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act. | ||||||
| 1 The trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed. | ||||||
(1)
On February 5, 2026, Jason Coloma, Chief Executive Officer, (a)terminated the Rule 10b5-1 trading arrangement adopted on October 13, 2025 to sell, between February 11, 2026 and July 14, 2026, up to 103,504 shares of our common stock, having sold no shares under such trading arrangement, and (b) adopted a new Rule 10b5-1 trading arrangement to sell, between May 8, 2026 and May 15, 2027, up to 414,012 shares of our common stock.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.